A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

03 Apr 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Locally Advanced Solid Tumors · Phase 1 · Enrollment 500 · Sponsor: Turning Point Therapeutics, Inc.

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Critical Care on 03 Apr 2026. The item focuses on A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements. Open the detail page to review the full original feed content.